13F-HR filed by Fairmount Funds Management LLC
Fairmount Funds Management LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 13 holding rows worth $1,313,784,318.
- Accession
- 0001104659-26-016303
- Filer
- CIK 1802528
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 13 entries on the cover page, a total value of $1,313,784,318 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,313,784,318 with VALUE read as dollars as filed, 13F file number 028-19908. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 9,003,418 | $319,801,407 | dollars as filed | |
| APOGEE THERAPEUTICS INC COM | 03770N101 | Stock | 2,048,647 | $154,631,876 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 4,018,101 | $131,632,989 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 3,914,458 | $121,817,933 | dollars as filed | |
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 3,705,262 | $112,306,491 | dollars as filed | |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 2,137,191 | $88,073,641 | dollars as filed | |
| ZENAS BIOPHARMA INC COM | 98937L105 | Stock | 2,209,025 | $80,209,698 | dollars as filed | |
| NUVALENT INC COM | 670703107 | Stock | 727,563 | $73,185,562 | dollars as filed | |
| JADE BIOSCIENCES INC | 008064206 | COM NEW | 4,553,494 | $70,260,412 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 3,711,444 | $57,156,238 | dollars as filed | |
| KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A | G52694109 | Stock | 1,319,688 | $54,437,130 | dollars as filed | |
| CRESCENT BIOPHARMA INC | G2545C104 | COMMON STOCK | 2,747,866 | $32,589,691 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 8,625,000 | $17,681,250 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-26-016303 | this filing | 2026-02-17 | acceptance time not in the bulk data set |